Cabiralizumab (FPA 008) 是一种抗
CSF1R单克隆抗体 (MAb)。Cabiralizumab 可增强 T 细胞浸润和抗肿瘤 T 细胞免疫反应。Cabiralizumab 抑制破骨细胞的活化并阻止骨质破坏，可用于类风湿性关节炎 (RA) 的研究。Cabiralizumab 可与 Nivolumab (HY-P9903) 结合用于肺癌研究。
| 生物活性 |
Cabiralizumab (FPA 008) is an anti-CSF1Rmonoclonal antibody (MAb). Cabiralizumab enhances T cell infiltration and antitumor T cell immune responses. Cabiralizumab inhibits the activation of osteoclasts and blocks bone destruction, and can be used in the research of rheumatoid arthritis (RA). Cabiralizumab can combine withNivolumab(HY-P9903) for lungcancerresearch[1][2].
|
| IC50& Target |
|
| CAS 号 |
|
| 储存方式 |
Please store the product under the recommended conditions in the Certificate of Analysis.
|
m.cnreagent.com
